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Abstract: One of the main mechanisms of action for photodynamic therapy (PDT) is the destruction
of tumor vasculature. We observed the PDT-induced vasculature destruction in a mouse model
of skin cancer using two techniques: Photoacoustic microscopy (PAM) and diffuse correlation
spectroscopy (DCS). PAM showed high-resolution images of the abnormal microvasculature near the
establishing tumor area at pre-PDT, as well as the subsequent destruction of those vessels post-PDT.
DCS indicated a significant blood flow decrease after PDT, confirming the vascular destruction.
Noninvasive assessment of vascular changes may be indicative of therapy response.
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1. Introduction
Nonmelanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell
carcinoma (SCC), are the most common human cancer with more than five million cases treated every
year [1]. Although they rarely metastasize, their management has become a real challenge to the health
care system due to extensive treatment costs [2]. In a significant portion of cases, the tumors can
originate in highly visible areas, such as the head and neck areas, including the face, and, thus, surgical
management may not be the most attractive option. Cryotherapy, laser and photodynamic therapy
(PDT) or a combination thereof may be an attractive alternative treatment option for the management
of NMSCs with good to excellent cosmetic outcomes [3].
Among these treatment alternatives we have been investigating PDT at preclinical and clinical
settings as a viable option for the management of NMSCs [4–6]. PDT is a light-based therapy
for tumor destruction that requires a combination of light, photosensitizer (PS) and oxygen [7,8].
Tumor destruction can be obtained by vascular shutdown, direct cell kill, activation of host immune
response, or a combination of these mechanisms [9,10]. Most PSs localize in the endothelium and can
induce substantial vascular changes during PDT, making microvasculature changes a good target for
monitoring the efficacy of PDT [6,11–16]. We have shown recently that blood flow changes assessed
with diffuse correlation spectroscopy (DCS), a diffuse optical spectroscopy method to quantify tissue
blood flow, can be indicative of PDT efficacy [17].
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Photoacoustic microscopy (PAM) can provide high-resolution images of microvasculature [18–21],
making it an attractive modality for monitoring PDT. Xiang et al. used photoacoustic tomography
for monitoring the vascular damage caused by PDT on a chicken embryo chorioallantoic membrane
(CAM) tumor model [22], although this setup does not readily translate to the clinic. Shao et al. recently
used PAM for PDT monitoring [23] in both a CAM and rat ear model, although neither model involved
a tumor. Here we implemented PAM for noninvasive monitoring of PDT in a transgenic mouse model
of skin cancer [4,24]. We imaged the microvasculature nearby a spontaneous BCC on a mouse ear
before, during and after PDT to assess the changes in the microvasculature. We also utilized diffuse
correlation spectroscopy (DCS) to measure the blood flow changes caused by PDT to investigate
potential correlation between microvasculature structure and function.
2. Materials and Methods
2.1. Animal and Tumor Model
All animal experiments followed protocols approved by the IACUC of Roswell Park Cancer
Institute (RPCI). Transgenic K5-Gli mice, which develop spontaneous BCCs, were acquired from
Dr. Andrezj Dlugosz at the University of Michigan and bred in our domestic colony [24].
Overexpression of Gli2 leads to increased activation of the Sonic hedgehog (Shh) pathway and increased
activation of Shh has been associated with BCCs in both human tumors and animal models [25].
Transgenic K5-Gli mice overexpress the Gli2 transcription factor in the epidermal basal layer and outer
root sheath of the hair follicles, developing spontaneous basal cell carcinomas (BCC) histologically
similar to human BCCs [26].
2.2. Custom PAM Imaging Setup
Our PAM setup utilized a 2D galvo scanning mirror system for raster scanning of laser
source [20,27]. A 532-nm pulsed laser (LUCE 820, Bright Solutions, Pavia, Italy) operating at 5 kHz
was steered through two achromatic lenses (f = 40 mm and 200 mm; AC254-040-A-ML and
AC254-200-A-ML, Thorlabs, Newton, NJ, USA) to expand and collimate the beam. A 92/8 beam
splitter (CM1-BP108, Thorlabs) directed a small portion of the light to a photodiode (DET10A, Thorlabs)
to measure the power of each pulse for normalization. The main beam was then directed to a
2D galvanometer scanning system (GVS002, Thorlabs) and focused onto the target using a 40-mm
achromat (AC254-040-A-ML, Thorlabs) as an objective. The maximum energy density of the focused
laser was 70 mJ/cm2, which is above the ANSI safety limit. A water tank was placed above the target
for an unfocused transducer (10 MHz, A311S-SU, Olympus, Waltham, MA, USA). The PA signal
was filtered and amplified before being digitized and saved by the computer. The water tank was
positioned so that the laser spot was focused on an imaging window in the bottom, which was covered
with clear plastic (Saran wrap, Johnson & Johnson, New Brunswick, NJ, USA). Ultrasound gel was
applied to the target, which was in contact with the underside of the imaging window. For each scan
the galvo steered the beam and at each stop multiple A-lines were acquired for averaging. The scan
followed a raster pattern, scanning all points in the x direction before transferring the data for saving,
returning to the initial x position and incrementing 1 step in the y direction for the next line. Each line
in the x direction took approximately 1.7 s and each step in the y direction took approximately 190 ms
and an entire scan took a little under 8 min. A picture of the setup is shown in Figure 1a and
a schematic is shown in Figure 1b.
To determine the resolution of our system, we scanned a 1951 USAF resolution target (R1DS1P,
Thorlabs). The resolution target was placed under the imaging window and gel was applied to
ultrasonically couple it ultrasonically couple it to the plastic. The scan was centered on group 5 of the
target with the long axis of the scan perpendicular to the line-pairs.
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Figure 1. Instrument setup. (a) a picture of the PAM setup; (b) a schematic of the setup and; (c) a 
picture of PDT being performed; (d) shows a picture of the mouse ear with the red area indicating the 
treatment region and the black dashed line outlining the tumor. 
2.3. Custom Diffuse Correlation Spectroscopy (DCS) Setup 
We used DCS to monitor changes in blood flow caused by PDT [16,28–35]. Briefly, the DCS 
setup consisted of a long coherence length, 785 nm laser (CrystaLaser), four photon-counting 
detectors (Perkin Elmer, Waltham, MA, USA) and a custom-built autocorrelator board 
(Correlator.com). The source was directed to the tissue by a multi-mode source fiber (400 μm core 
diameter) and collected with single-mode detector fibers (5 μm core diameter). The outputs from the 
photodetectors were sent to the correlator board to determine the intensity autocorrelation function 
and photon arrival times, which were then saved by the computer. The source-detector (SD) 
separations were 0.6, 1.0, 1.2 and 1.6 mm, providing a measure of blood flow at various depths in the 
tissue. Five measurements were acquired from multiple locations within the treatment area and 
relative blood flow (rBF) is reported as the mean and standard deviation of the change in blood flow 
from Pre-PDT. 
2.4. PAM and DCS Measurements during PDT  
A mouse from the breeding colony with a tumor at its ear was anesthetized with isoflurane and 
placed on a heating pad under the water tank. Ultrasound coupling gel was placed on the ear and 
the mouse was raised until the gel made contact with the imaging window. Pre-PDT PAM and DCS 
measurements were performed on the target area of the ear. The photosensitizer 
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) in dextrose 5% in water (D5W),  
0.47 μmol/kg [36] was injected via the tail vein. Figure 1c shows a picture of the experimental setup 
during PDT treatment. Pre-PDT PAM was performed before HPPH injection to minimize any 
photodynamic effect caused by the PAM laser. After a 1-h drug-light interval, 665 nm treatment light 
from a fiber-coupled argon-pumped dye laser was centered on the target area of the ear (red circle in 
Figure 1d). The fluence rate for the treatment light was 43 mW/cm2. After 1 min, treatment was 
paused while PAM and DCS measurements were performed to observe any early vascular changes. 
Measurements were only acquired at one time point during PDT to minimize any photodynamic 
effect from the PAM laser. Treatment then proceeded for nine more minutes for a total treatment 
time of 10 min.  
After light treatment, Post-PDT PAM and DCS measurements were performed on the target 
area. PAM images were shown as the maximum intensity projection (MIP) of each scan and each 
scan imaged the same area of the ear (5 mm × 5 mm, 20 μm step size). To quantify the change in 
vascularity due to PDT, vascular area was calculated as the percent area of the image above a certain 
threshold PA signal (3× the mean of the image). Vessel diameter was determined from the PAM 
images by using an edge detection method (Sobel, Matlab) to visualize the vessel boundaries and 
calculating the average widths of the same vessels visible at all three time points.  
  
Figure 1. Instrument setup. (a) a picture of the PAM setup; (b) a schematic of the setup and;
(c) a picture of PDT being performed; (d) shows a picture of the mouse ear with the red area indicating
the treatment region and the black dashed line outlining the tumor.
2.3. sto if use orrelation Spectroscopy (DCS) Setup
e used DCS to monitor changes in blood flow caused by PDT [16,28–35]. ri fl , the DCS
set consiste of a long coherence length, 785 nm laser (CrystaLaser), four photon-counting
detectors (Perkin Elmer, Waltham, MA, USA) and a custom-built autocorrelator board (Correlator.c m).
The source was direct d to th tissue by a multi-mode source fiber (400 µm core diameter) and collected
w th single-mode de ctor fibers (5 µm core diameter). The outputs from the p ot detecto s were
sent t th c relator board to determine the intensity autocorrelation function and photon arrival
times, which we e then saved by t e comput r. The source-dete tor (SD) separati ns were 0.6, 1.0, 1.2
and 1.6 mm, providing a measure of blood flow at v rious depths in the tissue. Five measurements
were acquired from ultiple locations within the treatment rea and relativ blood flow (rBF) is
reported as the mean and tanda d eviation of the change in blood flow from Pre-PDT.
2.4. PAM and DCS Measurements during PDT
A mouse from the breeding colony with a tumor at its ear was anesthetized with isoflurane
and placed on a heating pad under the water tank. Ultrasound coupling gel as placed on the
ear and the mouse was raised until the gel made contact with the imaging window. Pre-PDT
PAM and DCS measurements were performed on the target area of the ear. The photosensitizer
2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) in dextrose 5% in water (D5W),
0.47 µmol/kg [36] was injected via the tail vein. Figure 1c shows a picture of the experimental
setup during PDT treatment. Pre-PDT PAM was performed before HPPH injection to minimize any
photodynamic effect caused by the P laser. After a 1-h drug-light interval, 665 nm treatment light
from a fiber-coupled argon-pumped dye laser was centered on the target area of the ear (red circle
in Figure 1d). The fluence rate for the treatment light was 43 mW/cm2. After 1 min, treatment was
paused while PAM and DCS measurements were performed to observe any early vascular changes.
Measurements were only acquired at one time point during PDT to minimize any photodynamic
effect fro the PAM laser. Treatment then proceeded for nine more minutes for a total treatment ti e
of 10 min.
After light treatment, Post-PDT PAM and DCS measurements were performed on the target area.
PAM images were shown as the maximum intensity projection (MIP) of each scan and each scan
imaged the same area of the ear (5 mm ˆ 5 mm, 20 µm step size). To quantify the change in vascularity
due to PDT, vascular area was calculated as the percent area of the image above a certain threshold PA
signal (3ˆ the mean of the image). Vessel diameter was determined from the PAM images by using an
edge detection method (Sobel, Matlab) to visualize the vessel boundaries and calculating the average
widths of the same vessels visible at all three time points.
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3. Results
Our PAM scanner was capable of resolving group 5, element 6 of the 1951 USAF resolution target
(Figure 2a), indicating that the system had a resolution of 8.8 µm. Figure 2b shows the MIP and
Figure 2c shows the corresponding PA signal.
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We also observed PDT-induced blood flow changes (rBF) quantified by DCS, as summarized
in Figure 3f. After one minute, rBF decreased 33% (100% ˘ 34% to 67% ˘ 10%, p = 0.0007).
After ten minutes of treatment rBF decreased 60% (100% ˘ 34% to 40% ˘ 11%, p = 2.8 ˆ 10´9).
We also investigated whether vascular ischemia visualized by PAM correlated with the blood flow
changes. As observed before [22,23], we also measured a PDT induced vessel diameter decrease.
As shown in Figure 3g, a linear relationship was observed between the changes in vessel diameter and
rBF (r2 = 0.95).
4. Discussion
Qualitatively, there are few intact vessels visible in the post-PDT PAM image, while the pre-PDT
PAM image has several vessels and branches visible. Quantitatively, this is seen in the >90%
and 63% decrease in vascular area and vessel diameter, respectively, assessed with PAM and 60%
decrease in blood flow assessed with DCS. The two techniques provided complimentary assessment of
vascular destruction. There was a clear linear relationship between vascular parameters assessed with
PAM and DCS.
Despite the high resolution of the PAM imaging system, we could not measure very small
capillaries. There may be several reasons for this observation. First, our in vivo step size was 20 µm
in order to cover a larger area with the scan, which decreased the observable resolution limit.
Second, the mice overexpress the Gli2 transcription factor in the epidermal basal layer, which makes
the whole mouse ear skin thicker than that in healthy mice and gives the appearance of a rash.
Thus, photon diffusion is expected to dominate in deeper layer of the ear skin, resulting in lower
resolution and making it harder to image smaller microvessels. Third, no optical clearing agents were
used; thus, we expect the optical scattering in the ear skin was high. In addition, since the focal distance
is very critical to obtain the highest resolution imaging, rough tissue surface due to diseased skin in Gli
mice might have resulted in the variations in the focal length, which will affect the spot size. As Li et al.
have shown, a slight difference in height caused by a tumor can make an area appear devoid of vessels
and correcting the height of the scanner allows for improved visualization of microvasculature [37].
We will be adapting our system and algorithm to accommodate these types of physiological variations.
5. Conclusions
In this communication, we present results from a custom-built PAM and DCS system for
monitoring vascular changes during PDT in a mouse model of spontaneous skin cancer. PAM showed
vascular shutdown as seen by the decreased vessel area and vessel diameter post-PDT, while DCS
indicated substantial blood flow decrease complementing this vascular shut-down.
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